Latest Administration News

Page 53 of 164
OncoSil Medical reports a remarkable 917% increase in quarterly cash receipts alongside promising clinical trial results and key European market entries, signaling robust momentum in its pancreatic cancer treatment rollout.
Ada Torres
Ada Torres
30 Oct 2025
Paradigm Biopharmaceuticals has initiated dosing in its pivotal Phase 3 trial for knee osteoarthritis pain, backed by a strong cash position and strategic portfolio expansion. The company targets accelerated recruitment and a mid-2026 interim analysis.
Ada Torres
Ada Torres
30 Oct 2025
Future Metals NL appoints Keith Bowes as CEO and initiates a strategic review of its flagship Panton project, leveraging rising platinum group metal prices and exploration successes. The company also completes a A$4.2 million capital raise and plans to delist from AIM.
Maxwell Dee
Maxwell Dee
30 Oct 2025
AUCyber Limited reports a rise in customer receipts and improved operating cash flow in Q1 FY26, following strategic exits from low-margin contracts and a focus on cybersecurity services.
Sophie Babbage
Sophie Babbage
30 Oct 2025
Camplify Holdings reports a modest dip in revenue and transaction value due to poor weather, while maintaining positive cash flow and advancing its NSW TAP program rollout.
Sophie Babbage
Sophie Babbage
30 Oct 2025
Pantera Lithium Limited has secured a significant 5,000-acre exploration footprint in Southwest Arkansas, targeting antimony and silver in a historically rich but long-neglected mining district. This move aligns with U.S. critical minerals priorities and leverages Pantera’s proven local expertise.
Maxwell Dee
Maxwell Dee
30 Oct 2025
NeuroScientific Biopharmaceuticals has secured regulatory approval for initial patient treatments under its Special Access Program for StemSmart™ in Crohn’s disease, alongside key executive appointments and a manufacturing partnership to support upcoming clinical trials.
Ada Torres
Ada Torres
30 Oct 2025
Island Pharmaceuticals has completed its acquisition of the broad-spectrum antiviral Galidesivir and is progressing regulatory discussions with the FDA to fast-track approval using the Animal Rule, backed by compelling preclinical data.
Ada Torres
Ada Torres
30 Oct 2025
Fluence Corporation reported a robust 72.9% revenue increase year-to-date Q3 2025, fueled by the Ivory Coast Addendum project, while maintaining its full-year guidance despite some margin pressures.
Victor Sage
Victor Sage
30 Oct 2025
Fluence Corporation Limited reported a solid cash flow position for Q3 2025, with positive net cash from operations and strong liquidity supported by available financing facilities.
Sophie Babbage
Sophie Babbage
30 Oct 2025
TZ Limited reports steady sales growth and new Microsoft contracts in Q1 FY2026, reaffirming its $17–21 million revenue guidance amid improving market conditions.
Sophie Babbage
Sophie Babbage
30 Oct 2025
Petratherm Limited has significantly extended high-grade titanium mineralisation at its Rosewood East prospect and discovered a new Echo Prospect, advancing its Muckanippie Project towards a maiden resource.
Maxwell Dee
Maxwell Dee
30 Oct 2025